Micellar Paclitaxel to Treat Severe Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00006276
Recruitment Status : Completed
First Posted : September 15, 2000
Last Update Posted : March 4, 2008
Information provided by:
National Institutes of Health Clinical Center (CC)

Brief Summary:

This study will evaluate the safety and effectiveness of micellar paclitaxel for treating severe psoriasis. Paclitaxel in another formulation (Taxol) is approved by the Food and Drug Administration for use in patients with cancer. This drug can decrease growth of cancer cells and of new blood vessels. Because patients with psoriasis have an increase in skin cell and blood vessel growth, paclitaxel may also improve their condition. The dose of drug used in this study is much lower than those used to treat cancer patients and is expected to cause relatively few side effects.

Patients 18 to 70 years of age with psoriasis lesions affecting at least 20% of their skin may be eligible for this study. Candidates will be screened with a history and physical examination, blood and urine tests, electrocardiogram, and possibly an exercise stress test.

Participants will receive six intravenous (through a vein) infusions of paclitaxel over a 6-month period. Each infusion will take about 2 hours. Patients will stay in the clinic for observation for at least 1 hour before going home and will return to the clinic for follow-up examination and tests one week after each infusion. However, on weeks 0 and 8 visit will last for approximately 8 hours and will require a return to the clinic the following morning. Blood collection will be performed during the week 0 and 8 visits to determine how fast Micellar Paclitaxel is eliminated from your body. Approximately 2 teaspoons of blood will be taken prior to the infusion, twice during the infusion, and eight times during the 22 hours following the infusion for a total of eleven samples. These return visits will last approximately 1-2 hours. Patients will have the following procedures:

  1. A skin biopsy (removal of a small tissue sample for microscopic examination) will be done at the first visit (week 0) and again at weeks 6, 14 and 22. The area of the biopsy will be numbed with an anesthetic, and a small circle of skin about the width of a pencil eraser and half as deep will be cut and lifted away. Stitches will be placed and removed 1 to 2 weeks later.
  2. A history and physical examination will be done at every visit. Patients will be interviewed about changes in their skin condition and about treatment side effects and will be examined by a nurse or physician.
  3. Blood and urine samples will be collected at frequent intervals (nearly every visit) to test for side effects.
  4. Photographs of the skin will be taken at the first visit and at several later visits to document changes in psoriasis.
  5. A blood sample will be drawn for genetic testing to look for gene changes in people with psoriasis.
  6. An electrocardiogram will be taken at the last visit. This will be done at week 24 and compared to the screening EKG.
  7. Gonadal toxicity monitoring will be started with all patients entered into the protocol as of May 2001. Blood will be drawn to measure Inhibit A for females and Inhibit B for males at weeks 0, 6, 14, and 22.

Condition or disease Intervention/treatment Phase
Psoriasis Drug: Micellar Paclitaxel Phase 2

Detailed Description:
Paclitaxel is an antiangiogenic chemotherapeutic drug approved by the FDA for use in cancer. There is anecdotal evidence that some patients with cancer and concomitant psoriasis have shown improvement in their skin while receiving paclitaxel for cancer. Angiotech Pharmaceutical, Inc., the company with commercial rights over non-cancer uses of paclitaxel, has data that suggests paclitaxel demonstrates anti-inflammatory and immunomodulatory properties, in addition to the better known antiangiogenic and antiproliferative effects attributed to this compound. In this pilot open-label single-dose study, we initially treated patients with severe refractory psoriasis using intravenous Micellar Paclitaxel (75 mg/m(2) every 4 weeks) for six months. Because this dosing regimen was well tolerated and because the dosing interval seemed too long, we now propose to treat patients with intravenous Micellar Paclitaxel at the adjusted dose of 37.5 mg/m(2) every 2 weeks.

Study Type : Interventional  (Clinical Trial)
Enrollment : 25 participants
Primary Purpose: Treatment
Official Title: A Pilot Open-Label Single-Dose Study Using Intravenous Micellar Paclitaxel for Patients With Severe Psoriasis
Study Start Date : September 2000
Study Completion Date : October 2002

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis
Drug Information available for: Paclitaxel
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


Ability to provide informed consent to all aspects of the study after full information is provided.

Age equal or greater than 18 years, but not greater than 70 years old.

Severe psoriasis of at least 6 months duration as defined by the following criteria: Classic psoriatic skin lesions with or without nail involvement; PASI score greater than or equal to 20.

Therapeutic failure or inability to tolerate at least two alternative therapies for severe psoriasis (e.g., methotrexate, acitretin, cyclosporine A, PUVA, UVB, interleukin-10).

Ability to obtain intravenous access.

Negative urine pregnancy test (if female), and if pre-menopausal and sexually active, using two effective forms of contraception (one form being a barrier method).

WBC count greater than 5,000/mm(3).

Neutrophils greater than 2,500/mm(3).

Platelets greater than or equal to 125,000/mm(3).

Hemoglobin greater than or equal to 10 mg/dL.

Creatinine less than or equal to 1.4 mg/dL.

AST and ALT less than 2 times upper limits of normal.

Normal EKG (if any abnormalities suggestive of coronary artery disease then a normal stress thallium test will be required for entry).


Use of topical or systemic medications for psoriasis (except for bland emollients) during 2 weeks prior to study entry.

Pregnant or nursing women.

Current drug or alcohol abuse.

Evidence of HIV exposure or of chronic/active hepatitis.

Persons who are allergic to bee stings.

History of anaphylactic reactions.

Prior or concurrent malignancies, except non-melanoma skin cancer or carcinoma in situ of the cervix that have been adequately treated.

Any clinically significant past or current history of coronary artery disease.

Any confounding past or present medical illness that in the judgement of the investigators would pose added risk for study participants.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00006276

United States, Maryland
National Cancer Institute (NCI)
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Cancer Institute (NCI)

Publications: Identifier: NCT00006276     History of Changes
Other Study ID Numbers: 000211
First Posted: September 15, 2000    Key Record Dates
Last Update Posted: March 4, 2008
Last Verified: October 2002

Keywords provided by National Institutes of Health Clinical Center (CC):
Angiogenesis Inhibition
Skin Disease
Blood Vessels
Autoimmune Disease

Additional relevant MeSH terms:
Skin Diseases, Papulosquamous
Skin Diseases
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action